What this study is
The investigators are investigating whether home-based tDCS over the course of four weeks can improve ADHD symptom severity and improve dysexecutive functioning (cognitive control). Further, the investigators are investigating whether there is a dose-dependent response to tDCS.
What's being tested
- 2 mA transcranial direct current stimulation (tDCS)
Intervention · DEVICE
tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the 2mA condition, the investigators will assist the administration of a 2mA current stimulation from the device.
- 1 mA transcranial direct current stimulation (tDCS)
Intervention · DEVICE
tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the 1mA condition, the investigators will assist the administration of a 1mA current stimulation from the device.
- Sham transcranial direct current stimulation (tDCS)
Intervention · DEVICE
tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the sham condition, the investigators will assist the administration of a sham stimulation from the device.
Study details
- Sponsor
- Massachusetts General Hospital
- Conditions
- Attention Deficit Disorder · Attention Deficit Disorder With Hyperactivity
- Enrolling
- 60 people
- Starts
- 2022-07-01
- Est. completion
- 2026-05
- Design
- Quadruple-blind, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 65 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Male and female outpatients 18-65 years of age
- A diagnosis of ADD/ADHD or meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.
You can't join if
- Contraindication to tDCS: history or epilepsy, metallic implants in the head and neck, brain stimulators, vagus nerve stimulators, VP shunt, pacemakers, pregnancy.
- Active substance dependence (except for tobacco).
- Pregnant or nursing females.
- Inability to participate in testing procedures.
- Premorbid neurological conditions (including neurovascular and neurodegenerative diseases such as traumatic brain injury, stroke, Parkinson's, AD and other dementias) and severe psychiatric disorders (bipolar disorder, schizophrenia).
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openMassachusetts General Hospital
Charlestown, Massachusetts, United States
- DNN Inbox · Contact6177268780mghdnn@mgh.harvard.edu
Recruiting
Study team
Sponsor
Massachusetts General Hospital
Study ID 2022P000362
Principal investigator
Joan Camprodon, MD, PHD, MPH
MGB: Division of Neuropsychiatry and Neuromodulation
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.